Recurrence of Chronic Myeloid Leukemia during PregnancySubsequently Achieving Complete Medical Remission

The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) in reproductive-aged women posesmajor dilemmas concerning its associated teratogenicity as observed in many animal studies. Much controversy exists regardingcontinuation versus discontinuation of its use in pregnancy with some studies suggesting safety of TKIs before and during pregnancyand others reporting toxicity and adverse outcomes. TKIs have become a well-established treatment option for CML, significantlyimproving prognosis, and yet have been reported to be fetotoxic. We present a case of a 25-year-old woman who achieved successfulpregnancy and delivery after withholding treatment, meanwhile relapsing, eventually achieving complete molecular remission afterreinitiation of high dose dasatinib.